Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Research on cancer reported by scientists at Bayer Healthcare, Department of Cancer Biology
May 16th, 2008
Research findings, 'Generation of PEGylated VPAC1-selective antagonists that inhibit proliferation of a lung cancer cell line,' are discussed in a new report. According to recent research from the United States, "Vasoactive intestinal peptide (VIP) binds to two receptors, VPAC1 and VPAC2. Non-selective VIP antagonists have been shown to inhibit human cancer cell proliferation and reduce tumor growth in mice." "Many human cancers over-express VPAC1 but not VPAC2. We show that VPAC1-selective antagonists can inhibit human cancer cell proliferation and identify five positions in the VPAC1-selective antagonist PG 97-269 that may be responsible for VPAC1 selectivity....
Source: Health Business Week (2008-05-16)
|
